Vizgen is pushing the boundaries of spatial transcriptomics, providing researchers with both new insight into the biological processes that underlie human health and disease as well as next-generation tools that will drive innovation in drug discovery and diagnostics.

The company’s proprietary MERFISH (Multiplexed Error-Robust Fluorescence in situ Hybridization) technology is a quantitative and genome-scale multiplexed imaging platform for identifying nucleic acids in their native tissue environment with resolution scaling from subcellular to tissue scale. The technology has broad applications in both fundamental biology and medicine, ranging from basic science, to drug discovery, to clinical pathology.